BioSig (BSGM) and Its NeuroClear Subsidiary Are Leading the Way in Bioelectric Medicine with Amazing Potential
Good day everyone,
We are updating our coverage on BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace.
Current price $4.12 per share
Outstanding shares (est.) 32.1M
Shares in float (est.) 27.6M
Insider ownership 16.23%
Institutional ownership 18.8%
52-week high $9.77/share
The last time we reported on BSGM was in January of this year and we wanted to update you because a lot has happened in bringing their lead product to market and the company shares seem priced at a value. In addition, the company is developing new disruptive treatments utilizing the nervous system signals for certain indications.
Looking at the company stock chart we see that BSGM shares are above their 50 DMA of $3.50 and below their 200 DMA of $4.40/share.
If you’re not familiar with the BioSig PURE EP technology, it’s an advanced monitoring system currently used primarily for cardiac ablation procedures in patients with AFIB (atrial fibrillation) a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. At least 2.7 million Americans are living with AFib.
The company has begun to generate revenues from the PURE EP System. In April of this year BSGM introduced new software to guide the PURE EP system, incorporating feedback from doctors who have used it.
The company has been appearing at many cardiac conference events since the software upgrade giving PURE EP exposure to the professionals that could benefit from it. We anticipate the activity by the company in 2021, in addition to the new software release could generate new revenues for the company.
More than 940 patient cases have been conducted using the PURE EP™ System by 52 physicians in nine clinical sites to date.
What we really like about BSGM is that they are a pioneer in the field of bioelectric medicine with potential applications across various disease areas and disciplines, including neurology, auto-immune diseases, diabetes, arthritis, hypertension, pain management, cancer, and others.
Bioelectronic medicine is already a diverse, $20 billion market that includes familiar devices, such as pacemakers, as well as emerging technologies, such as vagus nerve stimulators and implantable neurostimulators.
Verily Life Sciences, Medtronic, and Johnson & Johnson are all making investments in bioelectric medicine and BSGM may benefit due to their unique technology providing more precise biomedical signals, and advanced signal processing capabilities.
NeuroClear (a BSGM majority owned subsidiary) and N-Sense
“Our nerves are constantly sending signals to every part of our bodies. What we need to do is listen to these signals and find a way to stimulate desired areas of indication.”– Ken Londoner, Chairman and CEO, NeuroClear (and Biosig).
N-Sense has conducted its first pre-clinical studies and was recently awarded the first patent exclusively licensed from the Mayo Foundation foe Medical Education and Research. The NeuroClear™ division is developing a novel nerve sensing and stimulation technology (N-Sense) to improve current treatments for resistant hypertension and other nerve-related therapeutic targets.
The science being developed at NeuroClear is different from anything we’ve looked at before and if it turns out to be viable, it could disrupt standards of care for many indications. This new concept of sending stimulation through the nervous system to treat nerve sensitive conditions could be the forefront of new medicine and BSGM is a pioneer in the sector. We include a short video about NeuroClear at this link. https://youtu.be/SECSQOrgAHA
Patents:
BioSig’s patent portfolio, includes nine allowed/issued patents. Sixteen additional worldwide utility patent applications that are pending covering various aspects of its PURE EP™ System. The Company has two additional pending U.S. patent applications directed to artificial intelligence (AI). BioSig has 24 allowed/issued worldwide design patents covering various features of its display screens and graphical user interface for enhanced visualization of biomedical signals. BioSig has exclusive licenses to 15 additional worldwide utility patent applications from Mayo Foundation for Medical Education and Research that are pending. These 15 applications are generally directed to electroporation and stimulation.
BSGM is revolutionizing the way we treat certain cardiac indications with their PURE EP system, and we believe 2021 may bring some decent revenues for that technology. The NeuroClear concept of treating ailments through nervous system stimulation is the stuff the future is made of. Let’s remember that the Mayo Clinic/Foundation, one of the top medical centers in the world, has been a collaborator/partner with BioSig through the development of PURE EP and NeuroClear. The University of Minnesota is also a partner in the development of N-Sense.
The amazing technology being developed at BSGM is likely to garner the interest of investors as well as others in the bioelectric medicine sector.
Stay tuned and stay informed,
The Traders News Group
Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
https://tradersnewssource.com/cookie-policy-us/
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Editor@TradersNewsSource.com
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated twenty two thousand five hundred dollars cash for our distributed opinions on bsgm this week. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.
